# Arsenal Biosciences

Source: https://onco.cc/companies/arsenal-bio/  
OnCo record `arsenal-bio` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Programmable CAR-T company using logic gates so cells fire only when two tumour proteins are present; AB-2100 (PSMA + CA9) is in phase 1/2 for kidney cancer.

## Summary

Arsenal Biosciences, based in South San Francisco, is a programmable CAR-T company that uses logic gates so its cells fire only when two tumour proteins are present, and its AB-2100 is in phase 1/2 for kidney cancer. AB-2100 combines a synthetic AND gate requiring both PSMA and CA9, shRNA armouring against suppression in the tumour microenvironment and a synthetic pathway activator, and is being tested in clear-cell renal cell carcinoma after immunotherapy and VEGF therapy in trial NCT06245915; AB-1015 targets ovarian cancer, and the company raised 325 million dollars with Regeneron and Bristol Myers Squibb participating. OnCo links it to renal and ovarian cancer, to armoured and logic-gated CARs and logic-gated therapeutics, and to PSMA as a target. Whether logic gating solves the on-target, off-tumour problem that has stalled solid-tumour CAR-T is the question its trial will test.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- Tags: frontier
- HQ: South San Francisco, CA
- Type: cell-therapy
- Website: https://arsenalbio.com

## Notes

- The Parker Institute for Cancer Immunotherapy's own news pages describe ArsenalBio as a company it launched in 2019, with a founders' interview on the institute's site.

## Sources

- AB-2100 trial: https://clinicaltrials.gov/study/NCT06245915
- PICI news: ArsenalBio: https://www.parkerici.org/?s=arsenalbio

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/)
- technologies: [Armoured, logic-gated & next-gen CARs](https://onco.cc/technologies/armored-car/), [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [Logic-gated therapeutics (AND, NOT gates)](https://onco.cc/technologies/logic-gated-therapeutics/)
- targets: [PSMA](https://onco.cc/targets/psma/)
- companies: [ARCH Venture Partners](https://onco.cc/companies/arch-venture-partners/), [Bristol Myers Squibb](https://onco.cc/companies/bms/), [Regeneron](https://onco.cc/companies/regeneron/)
- institutions: [Parker Institute for Cancer Immunotherapy](https://onco.cc/institutions/parker-institute/)
- trials: [AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)](https://onco.cc/trials/nct06245915/), [AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)](https://onco.cc/trials/nct07285694/)

---
JSON: https://onco.cc/api/v1/entities/arsenal-bio.json